Read the new Forrester report: The Total Economic Impact™ of Anaplan
Third-party research findings uncover a 303% ROI over a 3-year period across a composite of multiple customers
Evolving market demands and a complex commercial model for production, distribution, and reimbursement make the supply chain within life sciences a critical area in achieving growth and competitiveness within the business. The industry’s long development lead times, capacity constraints, high variability within the R&D pipeline, and reliance on contract manufacturing have added to the complexity of the planning process.
One of the common challenges life sciences companies face is the effective production and distribution capacity planning. This complexity has grown with the current priority on “cold chain” capacity for vaccine production, logistics, storage, and handling. The right investments in balancing critical resources such as people, capacity, and working capital can unlock significant value to both the business and the entire healthcare ecosystem.
Watch now to hear from Anaplan and Bluecrux about: